Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova‐Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H., & Rossi, J. (n.d.). a phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American journal of hematology, 90(1), 42–49. http://access.bl.uk/ark:/81055/vdc_100025006557.0x000004